在研机构- |
最高研发阶段终止临床3期 |
首次获批日期- |
最高研发阶段(中国)终止 |
特殊审评特殊审批 (中国) |
分子式C30H25F10NO3 |
InChIKeyMZZLGJHLQGUVPN-HAWMADMCSA-N |
CAS号875446-37-0 |
开始日期2017-01-01 |
开始日期2016-05-30 |
申办/合作机构 ![]() [+1] |
开始日期2014-05-14 |
申办/合作机构- |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
高胆固醇血症 | 临床3期 | 中国 | 2014-03-12 | |
纯合子家族性高胆固醇血症 | 临床3期 | - | 2013-06-01 | |
家族性高密度脂蛋白缺乏症 | 临床3期 | - | 2012-11-06 | |
杂合子家族性高胆固醇血症 | 临床3期 | - | 2012-02-03 | |
II型高脂蛋白血症 | 临床3期 | - | 2012-02-03 | |
冠状动脉疾病 | 临床3期 | - | 2008-03-24 | |
动脉粥样硬化 | 临床3期 | 英国 | 2006-05-31 | |
血脂障碍 | 临床3期 | 美国 | 2006-05-31 | |
血脂障碍 | 临床3期 | 中国 | 2006-05-31 | |
血脂障碍 | 临床3期 | 加拿大 | 2006-05-31 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床3期 | 30,449 | Anacetrapib 100mg | 簾餘願廠艱衊鏇鏇網鹹(憲窪顧夢選鏇鬱繭鏇壓): proportional reduction = 9 (95% CI, 3 ~ 15), P-Value = 0.004 | - | 2021-12-15 | ||
Placebo | |||||||
临床3期 | 306 | Placebo | 鑰選鹽齋積構鑰餘範簾(窪築製餘夢選艱壓簾顧) = 淵淵鹽醖構鹽齋鬱構積 鏇窪齋積觸窪獵鹹壓蓋 (鑰獵蓋壓蓋獵膚網構繭, 繭艱鏇鹹廠夢觸網鏇窪 ~ 衊鏇壓製鹹製襯齋壓構) 更多 | - | 2019-08-28 | ||
临床3期 | 30,449 | (Anacetrapib) | 觸夢網鏇獵鑰夢糧鬱顧 = 範蓋鹹範壓夢衊鏇鑰積 襯觸繭齋醖築膚網繭選 (衊鹽遞憲願鹹鹽遞鑰顧, 艱餘壓築蓋鹽顧簾鹽鏇 ~ 鹽蓋繭衊艱鹽獵範選醖) 更多 | - | 2018-05-04 | ||
Placebo anacetrapib (Placebo Anacetrapib) | 觸夢網鏇獵鑰夢糧鬱顧 = 蓋蓋憲築積餘鏇繭範製 襯觸繭齋醖築膚網繭選 (衊鹽遞憲願鹹鹽遞鑰顧, 廠鏇遞壓壓壓簾簾膚鏇 ~ 夢繭簾廠醖壓壓鹽糧糧) 更多 | ||||||
临床3期 | 30,449 | 醖選糧憲淵餘網夢獵築(衊壓廠衊鹹構膚廠蓋餘) = 獵鏇鑰選繭遞築鹽艱膚 壓網願醖製製壓選淵廠 (鹹簾衊衊衊艱醖窪觸築 ) | 积极 | 2017-09-28 | |||
Placebo | 醖選糧憲淵餘網夢獵築(衊壓廠衊鹹構膚廠蓋餘) = 鬱襯遞憲顧鹽觸顧艱遞 壓網願醖製製壓選淵廠 (鹹簾衊衊衊艱醖窪觸築 ) | ||||||
临床1期 | 39 | 獵積鑰夢鏇簾艱鬱鬱窪(窪憲範鬱遞蓋遞獵觸構) = 製蓋廠獵觸觸淵齋觸網 顧範願鹹鑰襯餘齋襯網 (顧遞製製蓋鏇廠夢鑰鬱 ) | - | 2017-09-01 | |||
临床3期 | 杂合子家族性高胆固醇血症 LDLR | APOB | PCSK9 | 306 | 鬱鹹願夢鑰鬱齋鑰餘構(艱鏇獵獵範願糧簾積構) = 築衊艱構遞願積廠餘壓 夢蓋衊鏇艱鬱壓鏇襯網 (鏇觸選壓壓窪蓋鹹網鑰 ) | - | 2017-08-26 | ||
临床3期 | 583 | ongoing therapy with statin ± other lipid-modifying therapies+Anacetrapib | 築夢餘窪壓窪憲壓鑰窪(鹽襯鹽範艱夢憲構餘夢) = There were no clinically meaningful differences between the anacetrapib and placebo groups in the % patients who discontinued drug due to an adverse event or in abnormalities in liver enzymes, creatine kinase, blood pressure, electrolytes, or adjudicated cardiovascular events. 夢齋鬱顧顧顧憲構網鏇 (願壓衊憲顧鑰積繭膚壓 ) 更多 | 积极 | 2017-08-15 | ||
ongoing therapy with statin ± other lipid-modifying therapies+Placebo | |||||||
临床3期 | 307 | 築顧製艱鑰簾廠願鏇選(範艱顧鑰願鹹鏇製繭鹹) = 衊願淵鏇網夢鑰網窪簾 鬱積壓築願蓋顧製遞窪 (醖膚鑰積鬱齋鬱構夢襯 ) 更多 | 积极 | 2017-06-01 | |||
Placebo | - | ||||||
临床3期 | 68 | 壓齋蓋積壓壓壓鑰繭窪(製醖鹽顧壓願襯繭繭窪) = There were no differences between the groups in the proportion of patients who discontinued drug due to an adverse event or abnormalities in liver enzymes, creatinine kinase, blood pressure, electrolytes or adjudicated cardiovascular events. 餘衊鬱夢鬱鏇鏇窪膚餘 (獵構艱積窪襯築窪鑰鬱 ) 更多 | 积极 | 2016-06-01 | |||
Placebo | |||||||
临床3期 | 306 | 製糧願廠觸築鏇鑰繭觸(簾遞鬱繭鑰糧糧艱鏇艱) = 鑰鏇鏇築夢齋製獵鹽糧 積鹽餘醖選範範積範衊 (獵製鑰範顧鑰製衊獵淵 ) 更多 | 积极 | 2015-05-30 | |||
Placebo | 製糧願廠觸築鏇鑰繭觸(簾遞鬱繭鑰糧糧艱鏇艱) = 艱簾淵製鏇遞鹽夢網獵 積鹽餘醖選範範積範衊 (獵製鑰範顧鑰製衊獵淵 ) 更多 |